ATE538199T1 - Ribosomenpräsentations- und mrna- präsentationsverfahren mit selektion hinsichtlich erhöhter stabilität des proteins - Google Patents

Ribosomenpräsentations- und mrna- präsentationsverfahren mit selektion hinsichtlich erhöhter stabilität des proteins

Info

Publication number
ATE538199T1
ATE538199T1 AT06700177T AT06700177T ATE538199T1 AT E538199 T1 ATE538199 T1 AT E538199T1 AT 06700177 T AT06700177 T AT 06700177T AT 06700177 T AT06700177 T AT 06700177T AT E538199 T1 ATE538199 T1 AT E538199T1
Authority
AT
Austria
Prior art keywords
presentation
selection
mrna
protein stability
ribosome
Prior art date
Application number
AT06700177T
Other languages
English (en)
Inventor
Andrew Buchanan
Lutz Jermutus
Original Assignee
Medimmune Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medimmune Ltd filed Critical Medimmune Ltd
Application granted granted Critical
Publication of ATE538199T1 publication Critical patent/ATE538199T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/10Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/102Mutagenizing nucleic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06Antianaemics
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/10Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034Isolating an individual clone by screening libraries
    • C12N15/1041Ribosome/Polysome display, e.g. SPERT, ARM
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/10Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034Isolating an individual clone by screening libraries
    • C12N15/1062Isolating an individual clone by screening libraries mRNA-Display, e.g. polypeptide and encoding template are connected covalently

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Diabetes (AREA)
  • Virology (AREA)
  • Urology & Nephrology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AT06700177T 2005-01-05 2006-01-05 Ribosomenpräsentations- und mrna- präsentationsverfahren mit selektion hinsichtlich erhöhter stabilität des proteins ATE538199T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US64220905P 2005-01-05 2005-01-05
GBGB0500099.7A GB0500099D0 (en) 2005-01-05 2005-01-05 Methods and means relating to protein variants
PCT/GB2006/000002 WO2006072773A1 (en) 2005-01-05 2006-01-05 Ribosome display or mrna display method with selection for increased stability of the protein

Publications (1)

Publication Number Publication Date
ATE538199T1 true ATE538199T1 (de) 2012-01-15

Family

ID=34179181

Family Applications (1)

Application Number Title Priority Date Filing Date
AT06700177T ATE538199T1 (de) 2005-01-05 2006-01-05 Ribosomenpräsentations- und mrna- präsentationsverfahren mit selektion hinsichtlich erhöhter stabilität des proteins

Country Status (11)

Country Link
US (2) US20070298430A1 (de)
EP (1) EP1833965B1 (de)
JP (1) JP5154947B2 (de)
CN (1) CN101180393A (de)
AT (1) ATE538199T1 (de)
AU (1) AU2006204424B2 (de)
CA (1) CA2593151C (de)
DK (1) DK1833965T3 (de)
ES (1) ES2379189T3 (de)
GB (2) GB0500099D0 (de)
WO (1) WO2006072773A1 (de)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60332358D1 (de) 2002-09-09 2010-06-10 Hanall Pharmaceutical Co Ltd Protease-resistente modifizierte interferon alpha polypeptide
GB0500099D0 (en) * 2005-01-05 2005-02-09 Cambridge Antibody Tech Methods and means relating to protein variants
CN101678079B (zh) * 2006-11-28 2013-12-25 韩诺生物制约株式会社 修饰的促红细胞生成素多肽及其治疗用途
ATE542830T1 (de) * 2006-12-04 2012-02-15 Pasteur Institut Als gerüst verwendeter ob-fold zur entwicklung neuer spezifischer bindemittel
US20120264686A9 (en) * 2008-05-29 2012-10-18 Hanall Biopharma Co. Ltd Modified erythropoietin (epo) polypeptides that exhibit increased protease resistance and pharmaceutical compositions thereof
MX2011003381A (es) * 2008-09-30 2011-04-21 Abbott Lab Metodo mejorado para despliegue de arn.
SG173747A1 (en) * 2009-02-18 2011-09-29 Univ Wayne State Method for identifying a subpopulation of mammalian cells with distinctive ribosome translation profiles
KR20140003467A (ko) 2010-12-20 2014-01-09 메디뮨 리미티드 항il-18 항체 및 그의 용도
CN103130893A (zh) * 2011-12-05 2013-06-05 中国人民解放军军事医学科学院卫生学环境医学研究所 己烯雌酚单链抗体筛选方法及其用途
RU2689674C2 (ru) 2012-10-15 2019-05-28 Медиммьюн Лимитед Антитела к бета-амилоиду
US12540318B2 (en) * 2012-11-08 2026-02-03 Roche Diagnostics Operations, Inc. Nucleic acids encoding chimeric polypeptides for library screening
US10421958B2 (en) 2014-02-05 2019-09-24 Molecular Templates, Inc. Methods of screening, selecting, and identifying cytotoxic recombinant polypeptides based on an interim diminution of ribotoxicity
EP3294773A1 (de) 2015-05-15 2018-03-21 The General Hospital Corporation Antagonistische anti-tumor-nekrosefaktorrezeptorsuperfamilienantikörper
CN109476695A (zh) * 2016-06-27 2019-03-15 丹娜法伯癌症研究院 用于测定rna翻译速率的方法
US11034951B2 (en) 2017-11-20 2021-06-15 Nantbio, Inc. mRNA display antibody library and methods
IL274780B2 (en) 2017-11-20 2025-04-01 Nantbio Inc mRNA library for antibody display and methods
CN113056487A (zh) 2018-09-18 2021-06-29 梅里麦克制药股份有限公司 抗tnfr2抗体及其用途
CN113366104B (zh) * 2019-01-31 2024-03-26 南特生物科学公司 mRNA展示抗体文库和方法
CN113874083A (zh) 2019-03-01 2021-12-31 梅里麦克制药股份有限公司 抗-tnfr2抗体及其用途
EP3953462A1 (de) * 2019-04-10 2022-02-16 Novozymes A/S Polypeptidvarianten

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008508854A (ja) * 2004-04-23 2008-03-27 ケンブリッジ アンティボディー テクノロジー リミテッド エリスロポイエチンタンパク質変異体
GB0500099D0 (en) * 2005-01-05 2005-02-09 Cambridge Antibody Tech Methods and means relating to protein variants

Also Published As

Publication number Publication date
GB0600147D0 (en) 2006-02-15
EP1833965B1 (de) 2011-12-21
AU2006204424A1 (en) 2006-07-13
DK1833965T3 (da) 2012-03-26
US20070298430A1 (en) 2007-12-27
JP2008526191A (ja) 2008-07-24
GB0500099D0 (en) 2005-02-09
EP1833965A1 (de) 2007-09-19
CA2593151A1 (en) 2006-07-13
AU2006204424B2 (en) 2011-09-08
US8288123B2 (en) 2012-10-16
CA2593151C (en) 2016-03-15
US20060183200A1 (en) 2006-08-17
CN101180393A (zh) 2008-05-14
JP5154947B2 (ja) 2013-02-27
GB2422606B (en) 2007-02-21
ES2379189T3 (es) 2012-04-23
WO2006072773A1 (en) 2006-07-13
GB2422606A (en) 2006-08-02

Similar Documents

Publication Publication Date Title
ATE538199T1 (de) Ribosomenpräsentations- und mrna- präsentationsverfahren mit selektion hinsichtlich erhöhter stabilität des proteins
AR062069A1 (es) Replegado de proteinas recombinantes
WO2008019123A3 (en) Enzyme sensors, methods for preparing and using such sensors, and methods of detecting protease activity
WO2005121163A3 (en) Isolation of plasma or serum proteins
WO2005118620A3 (en) Methods for preparing internally constraied peptides and peptidomimetics
WO2007064917A3 (en) Methods of preparation of recombinant forms of human beta-amyloid protein and uses of these proteins
DK1697523T3 (da) Ekspressionsvektor til antibiotikafri ekspression
CY1112924T1 (el) Κυτταροδιαπερατοι αναστολεις της jnk-σηματοδοτικης πορειας μεταγωγης
WO2005047511A3 (en) Bacterial expression of protease inhibitors and variants thereof
BRPI0512396A (pt) polipeptìdeos biossintéticos utilizando aminoácidos codificados não naturalmente
BR122018016045B8 (pt) proteína variante otimizada
DE60313659D1 (de) Borrelidin-derivate und ihre medizinische anwendung
WO2008127457A3 (en) Nucleic acids encoding recombinant protein a
WO2009139601A3 (en) Method and affinity column for purifying proteins
BRPI0913174A2 (pt) Método para produzir um hidrolisado de proteína de trigo, hidrolisado de proteína de trigo, e, uso de um hidrolisado de proteína de trigo.
WO2008034622A3 (en) A method of detecting and/or quantifying expression of a target protein candidate in a cell, and a method of identifying a target protein of a small molecule modulator
NO20071456L (no) Motorkontrollmodul og fremgangsmate for a bruke denne i motorsystemproduksjon
EP1641813A4 (de) Verfahren zur herstellung von molekülen mit verminderter immunogenität
NZ601647A (en) Variant hhip1 protein and methods and uses thereof
EA200702193A1 (ru) Гликозилирование белков
WO2008115296A3 (en) Modified phage for displaying post-translationally modified proteins and uses thereof
WO2008092030A3 (en) Specific n-terminal labeling of peptides and proteins in complex mixtures
WO2004108749A3 (en) Binding peptides: methods for their generation and use
WO2007063129A3 (en) Insolation of peptides , polypeptides and proteins
NO20055210D0 (no) Inhibitorproteiner av en protease og anvendelse derav